Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levofloxacin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.98 |
| ▸ | TUBB | P07437 | 7/20 | 0.98 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.98 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.98 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.98 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.98 |
| ▸ | TUBB3 | Q13509 | 7/20 | 0.98 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.98 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.98 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.98 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 0.98 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 0.98 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 0.98 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ofloxacin SCHEMBL27542046 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Levofloxacin Anhydrous SCHEMBL15397 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Ofloxacin SCHEMBL14163982 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Ofloxacin SCHEMBL24373 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Ofloxacin SCHEMBL5532921 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Ofloxacin SCHEMBL9745243 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Dextrofloxacine SCHEMBL4316947 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Levofloxacin Anhydrous SCHEMBL1442676 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Levofloxacin Anhydrous SCHEMBL1442440 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Ofloxacin SCHEMBL7719091 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224045-A1 | OTOLOGICAL SOLUTION FOR PREVENTING AND/OR TREATING OTITIS EXTERNA AND/OR OTITIS MEDIA | セオリアファーマ株式会社 | 2023-11-23 | — | — | WO | claimed |
| CN-111135182-A | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-105025930-A | Antibiotic conjugates linked with steroid drugs | ALLERGAN INC | 2015-11-04 | — | — | CN | claimed |
| CN-114668769-A | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-114668768-A | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-111135182-B | Antibacterial product and preparation method and application thereof | 心远(广州)药物研究有限公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-113495063-A | Antibacterial drug sensitivity test detection method based on fluorescent D-type amino acid metabolism marker | 上海交通大学医学院附属仁济医院 | 2021-10-12 | — | — | CN | disclosed |
| US-20210169924-A1 | PREVENTION AND TREATMENT OF OCULAR INFECTION, COMPOSITION AND METHODS THEREOF | CITY UNIVERSITY OF HONG KONG (CN) | 2021-06-10 | — | — | US | disclosed |
| WO-2020130652-A9 | NOVEL BACTERIOPHAGE FOR LYSING BACTERIA | 연세대학교 산학협력단 | 2020-10-22 | — | — | WO | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2020130652-A2 | NOVEL BACTERIOPHAGE FOR LYSING BACTERIA | 연세대학교 산학협력단 | 2020-06-25 | — | — | WO | disclosed |
| US-20110229544-A1 | Methods for Inhibiting Gram-Postive Bacteria Using Non-Phospholipid Lipid Vesicules | VIROBLOCK S.A. (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110212090-A1 | Combinatorial Analysis and Repair | DAKO DENMARK A/S | 2011-09-01 | — | — | US | disclosed |
| EP-2360160-A1 | Intermediates and their use for producing benzoxazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011084882-A2 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA | CONTRAFECT CORPORATION (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | DUKE UNIVERSITY (US) | 2011-07-14 | — | — | US | disclosed |
| US-7964723-B2 | And practical process for exclusively producing (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1,2,3,de][1,4]benzoxazine-6-carboxylic acid hemihydrate | APELOA-KANGYU (CN) | 2011-06-21 | — | — | US | disclosed |
| WO-2010141711-A1 | SKIN TREATMENT COMPOSITIONS | EX-TEK, LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| CN-1895305-A | Use of pharmacy for feline ginseng volatile oil | UNIV ZHEJIANG (CN) | 2007-01-17 | — | — | CN | disclosed |
| CN-1580055-A | Quinolone carboxylic acid derivatives and their salts | XINCHUANG MEDICINE SCIENCE TEC (CN) | 2005-02-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171195-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP | PDE7A, PDE8A, PDE8B | KDM4E 3141/4885ALDH1A1 1738/4885HPGD 329/4885 |
| US-20110229544-A1 | Methods for Inhibiting Gram-Postive Bacteria Using Non-Phospholipid Lipid Vesicules | PHOSPHO1, PGLS, PLA2G2C | KDM4E 2014/4885ALDH1A1 4728/4885HPGD 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.